FCGR3A and neoplasm: The PD-L1 inhibitor avelumab was used which represents an antibody with preserved effector functions that have been previously shown to induce direct tumor cell killing, especially in subjects expressing the FCGR3A high-affinity SNP rs396991 (Figure 1A).